Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 7/20 | 0.34 |
| ▸ | CYBB | P04839 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117686 | 0.81 | KDM4C (0.41) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL17767936 | 0.78 | KDM4C (0.46) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL17768193 | 0.78 | KDM4C (0.49) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL4988791 | 0.76 | NPC1 (0.44) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL15508893 | 0.76 | NPC1 (0.46) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL12959495 | 0.76 | KDM4C (0.45) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL15508907 | 0.75 | MEN1 (0.42) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL19175392 | 0.74 | KDM4C (0.43) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL171700 | 0.74 | L3MBTL1 (0.50) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL15508886 | 0.74 | KDM4C (0.43) | KDM4CNPC1RAB9AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2424866-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS -SECRETASE INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126745-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101093-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | KDM4C 2948/4885NPC1 289/4885RAB9A 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.